| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium
|
Ciliberto, Gennaro
|
|
|
222 |
C |
p.
|
artikel
|
| 2 |
Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025
|
Penel, Nicolas
|
|
|
222 |
C |
p.
|
artikel
|
| 3 |
Advances and challenges in targeted therapies for HER2-amplified colorectal cancer
|
Pizzamiglio, Margot
|
|
|
222 |
C |
p.
|
artikel
|
| 4 |
Artificial intelligence to predict cancer risk, are we there yet? A comprehensive review across cancer types
|
Felici, Alessio
|
|
|
222 |
C |
p.
|
artikel
|
| 5 |
Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study
|
Magaton, Isotta Martha
|
|
|
222 |
C |
p.
|
artikel
|
| 6 |
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin
|
Belkaïd, Samy
|
|
|
222 |
C |
p.
|
artikel
|
| 7 |
Association of comorbid schizophrenia with cancer stage at admission, treatments, length of stay, and 30-day in-hospital mortality in patients with pancreatic cancer: A retrospective matched-pair cohort study in Japan
|
Lin, Jiashiang
|
|
|
222 |
C |
p.
|
artikel
|
| 8 |
Clinical and imaging strategies for the assessment of the ocular side effects of systemic targeted anti-cancer therapies
|
Michaels, Luke
|
|
|
222 |
C |
p.
|
artikel
|
| 9 |
Corrigendum to “Association between local treatment modalities and event-free survival, overall survival, and local recurrence in patients with localised Ewing Sarcoma. Report from the Ewing 2008 trial” [Eur J Cancer 192 (2023) 113260]
|
Heesen, Philip
|
|
|
222 |
C |
p.
|
artikel
|
| 10 |
Corrigendum to “Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository” [Eur J Cancer 220 (2025) 115380]
|
Kitadai, Rui
|
|
|
222 |
C |
p.
|
artikel
|
| 11 |
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial
|
Hoeijmakers, L.L.
|
|
|
222 |
C |
p.
|
artikel
|
| 12 |
Editorial Board
|
|
|
|
222 |
C |
p.
|
artikel
|
| 13 |
Estimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe
|
Botta, Laura
|
|
|
222 |
C |
p.
|
artikel
|
| 14 |
German S2k-guideline on diagnostics, treatment and surveillance of low-grade appendiceal mucinous neoplasms (LAMN)
|
Köhler, Franziska
|
|
|
222 |
C |
p.
|
artikel
|
| 15 |
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
|
Jordan, Karin
|
|
|
222 |
C |
p.
|
artikel
|
| 16 |
Impact and safety of pregnancy on desmoid fibromatosis management in the era of active surveillance. An international multicenter retrospective observational study
|
Fiore, Marco
|
|
|
222 |
C |
p.
|
artikel
|
| 17 |
Letter comments on: “Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial”
|
Onal, Cem
|
|
|
222 |
C |
p.
|
artikel
|
| 18 |
Letter Re: Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
|
Agrawal, Mansi
|
|
|
222 |
C |
p.
|
artikel
|
| 19 |
Letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high-grade serous carcinoma
|
Karabuga, Berkan
|
|
|
222 |
C |
p.
|
artikel
|
| 20 |
Letter re: The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma
|
Liu, Wei
|
|
|
222 |
C |
p.
|
artikel
|
| 21 |
Mapping the potential for anti-PD-1 therapy in advanced rare skin carcinomas
|
Dessinioti, Clio
|
|
|
222 |
C |
p.
|
artikel
|
| 22 |
Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis
|
Labaki, Chris
|
|
|
222 |
C |
p.
|
artikel
|
| 23 |
Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials
|
Noronha, Mariana Macambira
|
|
|
222 |
C |
p.
|
artikel
|
| 24 |
Nordic colorectal cancer screening programmes: A comparison of organization, operation, and quality indicators
|
Jørgensen, Susanne Fogh
|
|
|
222 |
C |
p.
|
artikel
|
| 25 |
Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)： A phase III crossover trial
|
Zhang, Lulu
|
|
|
222 |
C |
p.
|
artikel
|
| 26 |
Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients
|
Ding, Nan
|
|
|
222 |
C |
p.
|
artikel
|
| 27 |
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG “PARCT”
|
Stadler, Rudolf
|
|
|
222 |
C |
p.
|
artikel
|
| 28 |
Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment
|
Imaoka, Hiroshi
|
|
|
222 |
C |
p.
|
artikel
|
| 29 |
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial
|
Biganzoli, Giacomo
|
|
|
222 |
C |
p.
|
artikel
|
| 30 |
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
|
Smolenschi, Cristina
|
|
|
222 |
C |
p.
|
artikel
|
| 31 |
Re: Guidance for discussants of randomized cancer trials at major meetings
|
Mazzocca, Alessandro
|
|
|
222 |
C |
p.
|
artikel
|
| 32 |
Response to letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial
|
Eminowicz, G.
|
|
|
222 |
C |
p.
|
artikel
|
| 33 |
Response to letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma
|
Hollis, Robert L.
|
|
|
222 |
C |
p.
|
artikel
|
| 34 |
Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England
|
Steventon, Luke
|
|
|
222 |
C |
p.
|
artikel
|
| 35 |
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study
|
Shamseddine, Ali
|
|
|
222 |
C |
p.
|
artikel
|
| 36 |
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
|
Xu, Jianming
|
|
|
222 |
C |
p.
|
artikel
|
| 37 |
Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000–2013: Results from EUROCARE-6, a population-based study
|
Trama, A.
|
|
|
222 |
C |
p.
|
artikel
|
| 38 |
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies
|
Moretto, R.
|
|
|
222 |
C |
p.
|
artikel
|
| 39 |
Trends in resection rates and postoperative mortality for gastrointestinal cancers between 2005 and 2020 in the Netherlands
|
Timmermans, Quince M.M.A.
|
|
|
222 |
C |
p.
|
artikel
|
| 40 |
Validation of the 9th Tumor, Node, and Metastasis Staging System for Patients with Surgically Resected Non-Small Cell Lung Cancer
|
Kim, Shia
|
|
|
222 |
C |
p.
|
artikel
|
Tijdschrift beschrijving